RXST vs. EYE, STAA, WRBY, EDAP, CLPT, BHC, STIM, APYX, BLCO, and ZLAB
Should you be buying RxSight stock or one of its competitors? The main competitors of RxSight include National Vision (EYE), STAAR Surgical (STAA), Warby Parker (WRBY), Edap Tms (EDAP), ClearPoint Neuro (CLPT), Bausch Health Companies (BHC), Neuronetics (STIM), Apyx Medical (APYX), Bausch + Lomb (BLCO), and Zai Lab (ZLAB). These companies are all part of the "medical" sector.
National Vision (NASDAQ:EYE) and RxSight (NASDAQ:RXST) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings, dividends and community ranking.
RxSight has lower revenue, but higher earnings than National Vision. RxSight is trading at a lower price-to-earnings ratio than National Vision, indicating that it is currently the more affordable of the two stocks.
78.8% of RxSight shares are held by institutional investors. 2.1% of National Vision shares are held by insiders. Comparatively, 21.1% of RxSight shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
National Vision received 223 more outperform votes than RxSight when rated by MarketBeat users. Likewise, 66.06% of users gave National Vision an outperform vote while only 62.50% of users gave RxSight an outperform vote.
National Vision has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500. Comparatively, RxSight has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500.
In the previous week, National Vision and National Vision both had 3 articles in the media. National Vision's average media sentiment score of 0.96 beat RxSight's score of 0.80 indicating that RxSight is being referred to more favorably in the news media.
National Vision presently has a consensus price target of $23.86, suggesting a potential upside of 7.66%. RxSight has a consensus price target of $49.63, suggesting a potential downside of 3.79%. Given RxSight's higher probable upside, equities analysts clearly believe National Vision is more favorable than RxSight.
National Vision has a net margin of -3.10% compared to National Vision's net margin of -54.57%. RxSight's return on equity of 3.69% beat National Vision's return on equity.
Summary
National Vision beats RxSight on 10 of the 17 factors compared between the two stocks.
Get RxSight News Delivered to You Automatically
Sign up to receive the latest news and ratings for RXST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RXST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools